Valeant Pharmaceuticals Intl Inc  

(Public, NYSE:VRX)   Watch this stock  
Find more results for VRX
20.44
+0.30 (1.49%)
After Hours: 20.56 +0.12 (0.59%)
Jul 1, 6:13PM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 19.83 - 21.65
52 week 18.55 - 263.81
Open 20.40
Vol / Avg. 31.06M/27.62M
Mkt cap 6.94B
P/E     -
Div/yield     -
EPS -2.14
Shares 341.19M
Beta 0.18
Inst. own 58%
Jul 21, 2016
Q2 2016 Valeant Pharmaceuticals International Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 14, 2016
Valeant Pharmaceuticals International Inc Annual Shareholders Meeting
Jun 10, 2016
Valeant Pharmaceuticals International Inc Annual Shareholders Meeting (Estimated)
Jun 7, 2016
Q1 2016 Valeant Pharmaceuticals International Inc Earnings Release
Jun 7, 2016
Q1 2016 Valeant Pharmaceuticals International Inc Earnings Call
May 23, 2016
Valeant Pharmaceuticals International Inc at UBS Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -15.72% -2.75%
Operating margin 2.79% 14.43%
EBITD margin - 45.71%
Return on average assets -3.05% -0.76%
Return on average equity -25.92% -5.21%
Employees 22,000 -
CDP Score - -

Address

Laval, 2150 Saint-Elzear Blvd W
LAVAL, QC H7L 4A8
Canada
+1-514-7446792 (Phone)
+1-514-7446272 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, CeraVe, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.

Officers and directors

Joseph C. Papa Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
Michael Pearson Chief Executive
Bio & Compensation  - Reuters
Robert L. Rosiello Chief Financial Officer, Executive Vice President
Age: 57
Bio & Compensation  - Reuters
Pavel Mirovsky President and General Manager, Europe
Age: 64
Bio & Compensation  - Reuters
Robert Roswell Chai-Onn Executive Vice President, General Counsel and Chief Legal Officer, Head of Corporate and Business Development, Director
Age: 44
Bio & Compensation  - Reuters
Ari S. Kellen Executive Vice President, Company Group Chairman
Age: 51
Bio & Compensation  - Reuters
Laizer D. Kornwasser Executive Vice President, Company Group Chairman
Age: 44
Bio & Compensation  - Reuters
Thomas W. Ross Sr. Lead Independent Director
Bio & Compensation  - Reuters
William A. Ackman Director
Age: 49
Bio & Compensation  - Reuters
Fredric N. Eshelman Independent Director
Bio & Compensation  - Reuters